	US 11,997,994 B2
	Genetically modified non-human animals with common light chain immunoglobulin locus
Yabo Zhang, Beijing (CN); Hui Lu, Beijing (CN); Huizhen Zhao, Beijing (CN); Jiawei Yao, Beijing (CN); Yi Yang, Beijing (CN); and Yuelei Shen, Beijing (CN)
Assigned to Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing (CN)
Filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing (CN)
Filed on Oct. 19, 2022, as Appl. No. 17/969,254.
Application 17/969,254 is a continuation of application No. PCT/CN2021/097652, filed on Jun. 1, 2021.
Claims priority of application No. PCT/CN2020/094000 (WO), filed on Jun. 2, 2020; and application No. PCT/CN2021/085839 (WO), filed on Apr. 7, 2021.
Prior Publication US 2023/0128645 A1, Apr. 27, 2023
Int. Cl. A01K 67/0278 (2024.01)

CPC A01K 67/0278 (2013.01) [A01K 2207/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/01 (2013.01)]

18 Claims

1. A genetically-modified mouse whose genome comprises at the endogenous kappa light chain immunoglobulin locus, an exogenous kappa light chain variable region gene sequence,

wherein the exogenous kappa light chain variable region gene sequence comprises only one human IGKV gene and only one human IGKJ gene,

wherein the human IGKV gene and the one human IGKJ gene are operably linked to an endogenous light chain constant domain gene, and the endogenous kappa light chain variable region gene sequence is nonfunctional, wherein

(1) the human IGKV gene is IGKV 1-39 and the human IGKJ gene is IGKJ4; or

(2) the human IGKV gene is IGKV 3-11 and the human IGKJ gene is IGKJ1,

wherein the mouse produces an antibody comprising a human light chain variable region (VL) in response to an antigen.